Bireme Capital's Evan Tindell on British American Tobacco $BTI and tobacco's inflection point

Episode Summary

Executive Summary: The episode centers on British American Tobacco as a deeply discounted tobacco stock with a high dividend, significant U.S. regulatory risk, and a growing next-generation products business. Evan argues the market is overfocusing on ESG and menthol/disposable-vape disruptions while underappreciating BAT’s cash generation, possible re-rating, and the value of its ITC stake.

Main Topics: BAT investment thesis and valuation (Priority: 5/5): BAT is presented as a cheap, high-cash-flow consumer products company trading at roughly 6-7x earnings with a 9-10% dividend yield, offering upside if the market re-rates it as reduced-risk products scale. Next-generation products and margin potential (Priority: 5/5): The conversation examines BAT’s vapes and nicotine pouches, whether they can be profitable at scale, and whether margins can approach those of legacy cigarettes despite more open competition and heavier commercial spending. Disposable vape disruption and regulatory enforcement (Priority: 5/5): A major near-term issue is illegal, flavored disposable vapes—often from China—taking share in the U.S. from BAT’s Vuse. The discussion questions whether regulators can meaningfully enforce existing rules. Menthol ban risk in the U.S. (Priority: 4/5): BAT is more exposed than peers to a potential FDA menthol-cigarette ban because Newport is a major U.S. brand. The episode discusses timing, political uncertainty, and BAT’s attempt to preserve value through reformulation/rebranding. ITC stake as hidden value (Priority: 4/5): BAT’s 29% stake in Indian tobacco/consumer conglomerate ITC is a significant asset relative to BAT’s market cap, though its monetization is uncertain and only partially reflected in the investment case. Capital allocation and acquisition risk (Priority: 4/5): There is concern that BAT could make value-destructive acquisitions instead of focusing on dividends, debt reduction, and buybacks. The ideal use of cash is seen as returning capital and paying down debt.

Key Arguments: BAT is cheap enough that even modest stability in the legacy business plus growth in reduced-risk products could drive attractive returns. ESG/ick-factor and European ownership constraints create a valuation discount that may persist despite BAT’s strong cash generation. Next-gen products should be profitable because they have similar retail pricing to cigarettes, lower tax burdens, and lower manufacturing costs at scale. The main threat to BAT’s U.S. vape business is illegal disposable products, not just competition within legal channels. The FDA and other agencies are trying multiple enforcement methods, but the market may persist until broader crackdowns become more systematic. A nationwide menthol ban would materially hurt BAT because menthol/Newport is a large share of its U.S. revenue. BAT’s ITC stake is meaningful enough to support the equity story, even if it cannot be fully monetized immediately. BAT should return cash via dividends/debt paydown; acquisitions would likely reduce the attractiveness of the thesis.

Data Points: BAT earnings multiple: ~6-7x earnings - Current valuation described as very cheap relative to history Dividend yield: ~9-10% - Indicated yield from BAT’s cash generation and payout policy BAT next-gen revenue share: a little more than 10% of revenue - Reduced-risk products have grown to a meaningful but still minority part of sales BAT next-gen guidance: 50% by 2030 - Company guidance for next-generation products as a share of revenue Philip Morris next-gen share: ~40% of business - Used as a peer comparison for ESG-sensitive investors BAT U.S. vape market share: almost 40% in the FDA-approved segment - Vuse is strong in the legal U.S. market Disposable vape share of market: ~50-60% - Estimate of illegal/disposable products dominating the broader U.S. market California menthol ban timing: end of 2022 - Ban that hurt BAT’s U.S. cigarette business BAT U.S. combustibles revenue share: 81% - Still heavily dependent on legacy cigarettes BAT tobacco business volume assumption: 5% volume decline and 3% price growth - Evan’s model assumption implies ~2% net revenue decline in legacy cigarettes BAT goodwill write-off: 2023 - Non-cash impairment discussed as a signal of weaker assumptions in legacy brands Palmall volume decline assumption: 19% five-year CAGR decline - Assumption disclosed in the goodwill impairment context Newport/Camel volume decline assumption: 11-12% five-year CAGR decline - Additional legacy brand assumptions in the impairment analysis ITC stake: 29% ownership - BAT’s large equity stake in Indian conglomerate ITC ITC stake value relative to BAT market cap: ~25-30% - Approximate stake value as a share of BAT’s equity value ITC dividend to BAT: $500-600 million annually - Cash flow BAT receives from its ITC holding ITC stake sale plan: 4% of the 29% stake - BAT signaled a partial sale but wants to stay above 25% ownership BAT legacy revenue dependence: ~85% from declining/legacy business - Highlighted concern that most revenue remains combustibles BAT legal/tax exposure on next-gen: unknowable / lower than cigarettes - No firm liability reserve disclosed; health risk believed much lower than combustibles

Pivotal Quotes: "If you can buy this thing for seven times earnings and they can grow the sort of reduced risk products revenue to become a material fraction of the overall business..." — Evan Tendill: Summarizing the core valuation thesis for BAT "I think my guess is that long-term, you know, if operating margin in cigarette business is 50%, I'm modeling like, just to be conservative, I'm modeling like 30%" — Evan Tendill: Explaining assumed profitability for next-generation products "Please, please don't let them do anything stupid." — Evan Tendill: Stressing his preference for dividends, debt paydown, and avoiding acquisitions

Implications: BAT looks like a classic high-cash-flow, low-multiple stock with multiple catalysts, but the thesis hinges on regulatory enforcement, menthol risk, and whether next-gen products can scale profitably. Investors are effectively betting that legality and cash returns outweigh legacy decline.